- Home
- NKTX vs CHEB Comparison
NKTX vs CHEB Comparison
Compare NKTX & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- CHEB
- Stock Information
- Founded
- NKTX 2015
- CHEB 2024
- Country
- NKTX United States
- CHEB Indonesia
- Employees
- NKTX N/A
- CHEB N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- CHEB
- Sector
- NKTX Health Care
- CHEB
- Exchange
- NKTX Nasdaq
- CHEB NYSE
- Market Cap
- NKTX 123.5M
- CHEB 122.8M
- IPO Year
- NKTX 2020
- CHEB 2024
- Fundamental
- Price
- NKTX $1.77
- CHEB $8.77
- Analyst Decision
- NKTX Strong Buy
- CHEB
- Analyst Count
- NKTX 6
- CHEB 0
- Target Price
- NKTX $14.40
- CHEB N/A
- AVG Volume (30 Days)
- NKTX 422.2K
- CHEB 110.7K
- Earning Date
- NKTX 08-12-2025
- CHEB 01-01-0001
- Dividend Yield
- NKTX N/A
- CHEB N/A
- EPS Growth
- NKTX N/A
- CHEB N/A
- EPS
- NKTX N/A
- CHEB N/A
- Revenue
- NKTX N/A
- CHEB N/A
- Revenue This Year
- NKTX N/A
- CHEB N/A
- Revenue Next Year
- NKTX N/A
- CHEB N/A
- P/E Ratio
- NKTX N/A
- CHEB N/A
- Revenue Growth
- NKTX N/A
- CHEB N/A
- 52 Week Low
- NKTX $1.31
- CHEB $6.09
- 52 Week High
- NKTX $8.23
- CHEB $13.70
- Technical
- Relative Strength Index (RSI)
- NKTX 46.34
- CHEB N/A
- Support Level
- NKTX $1.76
- CHEB N/A
- Resistance Level
- NKTX $2.08
- CHEB N/A
- Average True Range (ATR)
- NKTX 0.11
- CHEB 0.00
- MACD
- NKTX -0.00
- CHEB 0.00
- Stochastic Oscillator
- NKTX 25.00
- CHEB 0.00
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.